- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00616928
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
9 maggio 2018 aggiornato da: GlaxoSmithKline
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged ≥18 Years
The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity & safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
4561
Fase
- Fase 3
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- GSK Investigational Site
-
Truro, Nova Scotia, Canada, B2N 1L2
- GSK Investigational Site
-
-
Ontario
-
London, Ontario, Canada, N5W 6A2
- GSK Investigational Site
-
Sarnia, Ontario, Canada, N7T 4X3
- GSK Investigational Site
-
Sudbury, Ontario, Canada, P3E 6C3
- GSK Investigational Site
-
Woodstock, Ontario, Canada, N4S 4G3
- GSK Investigational Site
-
-
Quebec
-
Pointe-Claire, Quebec, Canada, H9R 4S3
- GSK Investigational Site
-
Quebec City, Quebec, Canada, G1E 7G9
- GSK Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 4J6
- GSK Investigational Site
-
St-Romuald, Quebec, Canada, G6W 5M6
- GSK Investigational Site
-
-
-
-
Alabama
-
Huntsville, Alabama, Stati Uniti, 35802
- GSK Investigational Site
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85020
- GSK Investigational Site
-
-
California
-
Anaheim, California, Stati Uniti, 92801
- GSK Investigational Site
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32216
- GSK Investigational Site
-
Melbourne, Florida, Stati Uniti, 32935
- GSK Investigational Site
-
Miami, Florida, Stati Uniti, 33143
- GSK Investigational Site
-
Pembroke Pines, Florida, Stati Uniti, 33024
- GSK Investigational Site
-
-
Georgia
-
Stockbridge, Georgia, Stati Uniti, 30281
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60610
- GSK Investigational Site
-
Peoria, Illinois, Stati Uniti, 61602
- GSK Investigational Site
-
-
Indiana
-
South Bend, Indiana, Stati Uniti, 46601
- GSK Investigational Site
-
-
Kansas
-
Lenexa, Kansas, Stati Uniti, 66219
- GSK Investigational Site
-
Wichita, Kansas, Stati Uniti, 67207
- GSK Investigational Site
-
-
Louisiana
-
Metairie, Louisiana, Stati Uniti, 70006
- GSK Investigational Site
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20850
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti, 63141
- GSK Investigational Site
-
-
Montana
-
Missoula, Montana, Stati Uniti, 59801
- GSK Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89104
- GSK Investigational Site
-
-
New Jersey
-
Edison, New Jersey, Stati Uniti, 08817
- GSK Investigational Site
-
-
New York
-
Poughkeepsie, New York, Stati Uniti, 12601
- GSK Investigational Site
-
Rochester, New York, Stati Uniti, 14609
- GSK Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, Stati Uniti, 27612
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44122
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, Stati Uniti, 16506
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Stati Uniti, 15236
- GSK Investigational Site
-
-
South Carolina
-
Spartanburg, South Carolina, Stati Uniti, 29303
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- GSK Investigational Site
-
Fort Worth, Texas, Stati Uniti, 76135
- GSK Investigational Site
-
San Angelo, Texas, Stati Uniti, 76904
- GSK Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- A male or female 18 years of age or greater at the time of the first vaccination.
- Written informed consent obtained from the subject.
- Among 18 to 49 year old subjects, good general health as established by medical history and clinical examination before entering into the study.
- Among subjects > 49 years of age, stable health status within 1 month prior to enrollment.
- Access to a consistent means of telephone contact.
- Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of short- and long-term safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits.
Exclusion Criteria:
- Evidence of substance abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subjectunable/unlikely to provide accurate safety reports.
- Diagnosed with cancer, or treatment for cancer, within 3 years.
- An oral temperature ≥37.8º C, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
- Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus infection.
- Receipt of systemic glucocorticoids within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment.
- Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.
- Administration of any vaccines within 30 days before study enrollment.
- Previous administration of any H5N1 vaccine.
- Use of any investigational or non-registered product or planned participation in another investigational study within 30 days prior to study enrollment, or during the 364 days following the first test article dose. Use of any investigational or non-registered product with immunosuppressive properties is exclusionary at any time during the trial.
- Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period.
- Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.
- Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to either vaccination.
- Lactating or nursing.
- Women of child bearing potential who lack a history of reliable contraceptive practices. The provision of this history does NOT replace the requirement to perform, and obtain negative results in pregnancy urine tests prior to treatments.
- Known use of an analgesic or antipyretic medication within 12 hours prior to first treatment.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Influenza A (H5N1) 18-64Y Group
Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Comparatore placebo: Placebo 18-64Y Group
Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Sperimentale: Influenza A (H5N1) >64Y Group
Subjects aged > 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Comparatore placebo: Placebo >64Y Group
Subjects aged > 64 years, who received 2 doses of placebo at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Sperimentale: Influenza A (H5N1) Group
Pooled group of subjects aged >18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Comparatore placebo: Placebo Group
Pooled group of subjects aged >18 years, who received 2 doses of placebo at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Sperimentale: Influenza A (H5N1) 18-60Y Group
Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Comparatore placebo: Placebo 18-60Y Group
Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Sperimentale: Influenza A (H5N1) >60Y Group
Subjects aged >60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Comparatore placebo: Placebo >60Y Group
Subjects aged > 60 years, who received 2 doses of placebo at Days 0 and 21.
The first dose was administered in the deltoid region of the non-dominant arm.
The second dose was administered in the deltoid region of the dominant arm.
|
Two intramuscular injections at Days 0 and 21.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)
Lasso di tempo: At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer < 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.
|
At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)
Lasso di tempo: At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
|
At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
Number of Subjects With Any Solicited Local Symptoms.
Lasso di tempo: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
|
During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
|
Number of Subjects With Any Solicited General Symptoms.
Lasso di tempo: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
|
Assessed solicited general symptoms were fatigue, headache, joint pain at other locations, muscle aches, shivering, sweating and temperature[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)].
Any = occurrence of the symptom regardless of intensity grade.
|
During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
|
Number of Subjects With Any Unsolicited Adverse Events (AEs).
Lasso di tempo: During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)
|
Number of Subjects With Serious Adverse Events (SAEs)
Lasso di tempo: From Day 0 through Day 182 and through Day 379.
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From Day 0 through Day 182 and through Day 379.
|
Number of Subjects With Medically Attended Events (MAEs)
Lasso di tempo: From Day 0 through Day 182 and through Day 364.
|
From Day 0 through Day 182 and through Day 364.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Subjects With Serum Reciprocal HI Antibodies Against A/Indonesia/5/2005 Equal to or Above (≥) 1:10
Lasso di tempo: At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
|
Number of Subjects With A/Indonesia/5/05 Antibody Titers ≥ 1:10
Lasso di tempo: At Month 6 (Day 182) post Dose 1
|
At Month 6 (Day 182) post Dose 1
|
|
Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)
Lasso di tempo: At Month 6 (Day 182) after Dose 1
|
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer < 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.
|
At Month 6 (Day 182) after Dose 1
|
Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)
Lasso di tempo: At Month 6 (Day 182) after Dose 1
|
At Month 6 (Day 182) after Dose 1
|
|
Titers for Serum HI Antibodies Against A/Indonesia/5/05 (H5N1)
Lasso di tempo: At Month 6 (Day 182) after Dose 1
|
Titers are presented as geometric mean titers (GMTs).
The reference seropositivity cut-off value was ≥ 1:10.
|
At Month 6 (Day 182) after Dose 1
|
Number of Subjects With a Vaccine Response to the Vaccine-homologous Virus and Drift Variant H5N1 Virus, as Assessed by Microneutralization Assays.
Lasso di tempo: At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
Virus antibody response rates were defined as the number of subjects with antibody titers at Day 42 ≥ 4-fold the pre-vaccination antibody titers.
The 2 strains assessed were Flu A/Indonesia/5/05 and Flu A/Vietnam/1194/04.
|
At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1) as Assessed by Microneutralization Assays
Lasso di tempo: At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
Titers were expressed as Geometric Mean Titers (GMTs).
|
At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
23 gennaio 2008
Completamento primario (Effettivo)
15 ottobre 2008
Completamento dello studio (Effettivo)
19 marzo 2009
Date di iscrizione allo studio
Primo inviato
28 gennaio 2008
Primo inviato che soddisfa i criteri di controllo qualità
5 febbraio 2008
Primo Inserito (Stima)
15 febbraio 2008
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
8 giugno 2018
Ultimo aggiornamento inviato che soddisfa i criteri QC
9 maggio 2018
Ultimo verificato
1 ottobre 2016
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 110464
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Dati/documenti di studio
-
Piano di analisi statistica
Identificatore informazioni: 110464Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Rapporto di studio clinico
Identificatore informazioni: 110464Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Modulo di segnalazione del caso annotato
Identificatore informazioni: 110464Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Set di dati del singolo partecipante
Identificatore informazioni: 110464Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Specifica del set di dati
Identificatore informazioni: 110464Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Modulo di consenso informato
Identificatore informazioni: 110464Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocollo di studio
Identificatore informazioni: 110464Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .